The Mild Traumatic Brain Injury Treatment market is expected to witness a CAGR of 3.8% during the forecast period. Certain factors that are driving the market growth include increasing incidence of mild traumatic brain injuries, and ongoing product development and approval.
Mild traumatic brain injury (MTBI) is a frequent medical condition, and some patients report long-lasting problems after MTBI. In order to prevent MTBI, knowledge of epidemiology is an important, and potential bias in studies should be explored. Traumatic brain injury (TBI) is a complex injury comprising a spectrum from mild TBI (MTBI) with low risk of persistent disability, to the most severe TBI with devastating brain damage. However, MTBI constitutes 80–90 % of all TBI. Therefore the rising incidences and injuries being caused to the brain worldwide resulting in a high prevalence of target disorders are expected to impact the market in a positive manner.
Key Market Trends
Hospital is Expected to Hold Significant Market Share in the End User Segment
The therapy for mild traumatic brain injury treatment usually begins in the hospital and continues at an inpatient rehabilitation unit, a residential treatment facility, or through outpatient services. The type and duration of rehabilitation are different for everyone, depending on the severity of the brain injury and what part of the brain was injured. People with mild traumatic brain injuries may also have other injuries that need to be addressed.
Additional treatments in the emergency room or intensive care unit of a hospital generally focus on minimizing secondary damage due to inflammation, bleeding, or reduced oxygen supply to the brain.
North America Dominates the Market and Expected to do Same in the Forecast Period
Traumatic brain injury (TBI), also known as acquired brain injury, head injury, or brain injury, causes substantial disability and mortality in the American population. It occurs when a sudden trauma damages the brain and disrupts normal brain function. TBI often has profound physical, psychological, cognitive, emotional, and social effects on the lives of American people. Mild TBI appears to be vastly under-diagnosed in the setting of systemic trauma, even in trauma centers. According to the CDC, there were approximately 2.8 million TBI-related emergency department visits, hospitalizations, and deaths in the United States in 2015. Hence, the rising prevalence of MTBI is expected to drive the overall growth of the market across the entire region.
The global Mild Traumatic Brain Injury Treatment market is highly competitive and consists of a number of major players. Companies like Grace Laboratories LLC., Integra LifeSciences Corporation, Medtronic PLC, Neuren Pharmaceuticals Ltd., NeuroVive Pharmaceutical AB , Stemedica Cell Technologies Inc., TEVA Pharmaceutical Industries Ltd., Vasopharm GmbH, among others, hold the substantial market share in the Mild Traumatic Brain Injury Treatment market.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support